You searched for "retention"
Endoscopic management of upper tract urothelial carcinoma
Upper tract urothelial carcinoma (UTUC) is a rare disease accounting for 5-10% of all urothelial carcinomas and has an annual incidence in Western countries of 1-2 per 100,000 [1,2]. It occurs more commonly in the pelvicalyceal system as opposed to...TURP
In this series of articles I am going to show you some of the exhibits contained in the BAUS Virtual museum of the History of Urology which is part of the BAUS website (www.baus.org.uk). In the last article I told...The surgical management of female stress urinary incontinence in a post-mesh era
Trends in surgical management of women with stress urinary incontinence (SUI) have changed in recent times, mainly due to the ‘High Vigilance Pause’ placed on the use of mesh for SUI (and prolapse) surgery in July 2018 following an independent...Francisco Díaz (1527-1590), forefather of urology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). We often talk about urology being the oldest surgical specialty and discuss the...
Beware of the ambiguous testicular lump
In busy day-to-day practice, we are often faced with puzzling situations. A useful mnemonic is 4-T: torsion, trauma, tumour and tuberculosis (infections). This case review in the BMJ is about a 34-year-old man presenting to A&E with left testicular pain...So you want to be a urologist?
Urology is a varied, innovative and friendly speciality and it is easy to see why so many people are attracted to it. The article below is designed to help all doctors wishing to apply for an ST3 post get the...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...Frailty in urology – part 1
Part 2 of this topic can be found here Statement of the problem Clinical frailty carries an increased risk of poor health outcomes. The pathological process resulting in frailty is often overlooked and elucidating its aetiology and natural history are...Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...BAUS Annual Scientific Meeting 2024
Day 1 Toni Huw Mihailidis and Mriganka Mani Sinha Another year and another brilliant meeting in which urologists from the UK and around the globe assembled for a highly entertaining event. Day one kicked off with a topical and ever-pervasive...
